Search
170 studies match these filters. Showing 101–125 of 170 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT05125302 | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how sa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 129 sites in total | Recruiting | Phase 3 | 1,059target | 129 / 2 | 2022 | Sep 14, 2026 | |
| NCT05065216 | Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limit… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 86 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 728target | 86 / 10 | 2021 | Sep 14, 2026 | |
| NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 34 sites in total · contact listed | Recruiting | Phase 3 | 383target | 34 / 3 | 2023 | Sep 11, 2026 | |
| NCT07619131 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment… ✓ Contact✗ Claimed Nearest site: Derby, Kansas, United States — 54 km away · 152 sites in total | Recruiting | Phase 3 | 600target | 152 / 11 | 2026 | Sep 10, 2026 | |
| NCT06567743 | Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 80 sites in total · contact listed | Recruiting | Phase 2 | 325target | 80 / 2 | 2024 | Sep 3, 2026 | |
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blo… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 582 sites in total | Recruiting | Phase 2 | 314target | 582 / 2 | 2019 | Nov 18, 2026 | |
| NCT07674654 | A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total | Recruiting | Phase 3 | 1,000target | 113 / 1 | 2026 | Nov 2, 2026 | |
| NCT07645924 | A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 113 sites in total · contact listed | Recruiting | Phase 3 | 1,800target | 113 / 1 | 2026 | Nov 2, 2026 | |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 9 sites in total | Recruiting | Phase 1 / Phase 2 | 155target | 9 / 1 | 2026 | Sep 28, 2026 | |
| NCT07761117 | A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF),… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 679 sites in total | Recruiting | Phase 3 | 6,950target | 679 / 32 | 2026 | Sep 28, 2026 | |
| NCT05172960 | ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4/X4S Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 65 sites in total | Recruiting | Not applicable | 1,234target | 65 / 4 | 2022 | Sep 24, 2026 | |
| NCT07662044 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucos… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 149 sites in total | Recruiting | Phase 3 | 800target | 149 / 13 | 2026 | Aug 31, 2026 | |
| NCT07226791 | Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 13 sites in total | Recruiting | Phase 2 | 200target | 13 / 1 | 2026 | Aug 25, 2026 | |
| NCT05677100 | Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 50 sites in total | Recruiting | Not applicable | 320target | 50 / 2 | 2023 | Aug 25, 2026 | |
| NCT07000357 | A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 1,452 sites in total | Recruiting | Phase 3 | 15,100target | 1,452 / 36 | 2025 | Aug 24, 2026 | |
| NCT07567001 | A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 838 sites in total | Recruiting | Phase 3 | 5,610target | 838 / 27 | 2026 | Aug 18, 2026 | |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or targeted therapy with osimertinib) versus the usual treatment alone… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 477 sites in total · contact listed | Recruiting | Phase 3 | 474target | 477 / 2 | 2023 | Aug 17, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT06571669 | BOOM-IBD2 Pivotal Clinical Trial Ulcerative colitis is a long-lasting condition that causes swelling and sores in the large intestine. This study tests whether a small device placed under the skin can help reduce bowel urgency in people with ulcerative colitis. The investigational device sends mild signals to a nerve near the tailb… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 19 sites in total · contact listed | Recruiting | Not applicable | 137target | 19 / 1 | 2025 | Aug 6, 2026 | |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemoth… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 846 sites in total · contact listed | Recruiting | Phase 3 | 1,295target | 846 / 3 | 2023 | Aug 5, 2026 | |
| NCT06909565 | Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin th… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 153 sites in total · contact listed | Recruiting | Phase 4 | 6,000target | 153 / 1 | 2025 | Nov 16, 2026 | |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 254 sites in total | Recruiting | Phase 3 | 540target | 254 / 27 | 2025 | Nov 5, 2026 | |
| NCT06547489 | Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 34 sites in total | Recruiting | Phase 2 | 164target | 34 / 1 | 2025 | Aug 3, 2026 | |
| NCT07610278 | A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia This is a multicenter, randomized, double-blind, factorial design Phase 2 study to evaluate the pharmacodynamics, safety and tolerability of a combination of QCZ484 and inclisiran compared to QCZ484, inclisiran, and placebo in participants with hypertension and concomitant hypercholesterolemia. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 29 sites in total · contact listed | Recruiting | Phase 2 | 120target | 29 / 1 | 2026 | Jul 30, 2026 | |
| NCT06937177 | Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) o… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 26 sites in total · contact listed | Recruiting | Phase 2 | 120target | 26 / 2 | 2025 | Jul 15, 2026 |